uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
October 05, 2023 07:05 ET
|
uniQure Inc.
~ Reduction of 28% of workforce not related to HEMGENIX® manufacturing obligations; Total cost savings of $180 million to extend cash runway into second quarter of 2027 ~ ~ Discontinuing investments...
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Oct. 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
[Latest] Global Hemophilia B Gene Therapy Market Size/Share Worth USD 5,938.5 Billion by 2032 at a 34.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
September 27, 2023 16:00 ET
|
Custom Market Insights
Austin, TX, USA, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Hemophilia B Gene Therapy Market Size, Trends and Insights By Treatment Type...
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
September 05, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Sept. 05, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Gene Vector Market to hit USD 4 billion by 2032, says Global Market Insights Inc.
August 13, 2023 20:15 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Aug. 13, 2023 (GLOBE NEWSWIRE) -- Gene Vector Market size will cross USD 4 billion by 2032. Consistent advancement in gene therapy will support industry progression over the...
Cell & Gene Therapy Drug Delivery Devices Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028
August 03, 2023 06:47 ET
|
ReportLinker
New York, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell & Gene Therapy Drug Delivery Devices Market- Global Industry Size, Share, Trends,...
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 01, 2023 07:05 ET
|
uniQure Inc.
~ Announced encouraging interim analysis data from ongoing Phase I/II clinical trial of AMT-130 in Huntington’s disease showing preservation of function compared to baseline and clinical benefits...
uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
June 26, 2023 07:11 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 26, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
June 21, 2023 07:05 ET
|
uniQure Inc.
~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural...
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
June 20, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 20, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...